LUCD · CIK 0001799011 · operating
Lucid Diagnostics develops diagnostic tools for early detection of esophageal precancerous conditions in patients with gastroesophageal reflux disease (GERD). The company's primary offering is the EsoGuard Esophageal DNA Test, which analyzes cell samples collected using the EsoCheck Esophageal Cell collection device. The testing platform targets patients at risk of esophageal adenocarcinoma (EAC), a highly lethal cancer type, with the goal of identifying precancerous changes before invasive disease develops.
The company operates as a commercial-stage diagnostics enterprise, currently focused on bringing its core testing product to market. Revenue generation centers on the EsoGuard test offerings, though the company remains in an early commercialization phase. Lucid Diagnostics functions as a subsidiary of PAVmed Inc., a broader medical technology company.
Based in New York, New York, the company operates with a workforce of approximately 72 full-time employees. The business serves the U.S. healthcare market, with operations concentrated domestically. Lucid Diagnostics is incorporated in Delaware and trades on the Nasdaq exchange under the ticker LUCD.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2024 | $-1.05 | $-1.05 | +16.7% | |
| 2023 | $-1.26 | $-1.26 | +18.7% | |
| 2022 | — | $-1.55 | — | |
| 2021 | — | — | — |